America Great Health (AAGH) 10-Q 21 Feb 23 2023 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Dec. 31, 2022	Feb. 21, 2023
Document Information Line Items
Entity Registrant Name	America Great Health
Trading Symbol	N/A
Document Type	10-Q
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding		21,090,218,148
Amendment Flag	false
Entity Central Index Key	0001098009
Entity Current Reporting Status	No
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-27873
Entity Incorporation, State or Country Code	WY
Entity Tax Identification Number	98-0178621
Entity Address, Address Line One	1609 W Valley Blvd Unit 338A
Entity Address, City or Town	Alhambra
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91803
City Area Code	888
Local Phone Number	988-1333
Title of 12(b) Security	N/A
Security Exchange Name	NONE
Entity Interactive Data Current	No

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Jun. 30, 2022
CURRENT ASSETS
Cash	$ 51,197	$ 62,643
Account receivable, net	726	918
Inventory	113,949	116,060
Advance to supplier	16,965	16,964
TOTAL CURRENT ASSETS	182,837	196,585
Right-of-use asset	58,069	93,886
Due from the related parties	8,218	8,218
Deposit	11,836	13,836
Property and equipment, net	65,086	23,618
TOTAL ASSETS	326,046	336,143
CURRENT LIABILITIES
Accounts payable	1,442,897	1,437,522
Tax payable	1,007	102
Short term loan	179,750	183,932
Other payable	347,573	334,112
Due to related party	595,350	573,859
Deferred income	198,699	157,000
Lease liability - current	58,069	70,895
TOTAL CURRENT LIABILITIES	2,823,345	2,757,422
Lease liability - non current	0	22,991
Accrued liability	510,107	384,073
Long term loan	1,153,138	1,032,138
TOTAL LIABILITIES	4,486,590	4,196,624
Commitments and Contingencies	0	0
SHAREHOLDERS' DEFICIT
Redeemable, convertible preferred stock, 10,000,000 shares authorized; Series A voting preferred stock, zero shares issued and outstanding	0	0
Common stock, no par value, unlimited shares authorized; 21,090,218,148 and 21,090,218,148 shares issued and outstanding	0	0
Additional paid-in capital	4,640,397	4,619,991
Accumulated other comprehensive income	566	160
Accumulated deficit	(8,728,754)	(8,421,849)
TOTAL AMERICA GREAT HEALTH SHAREHOLDERS' DEFICIT	(4,087,791)	(3,801,698)
Non-controlling interest	(72,753)	(58,783)
TOTAL SHAREHOLDERS' DEFICIT	(4,160,544)	(3,860,481)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$ 326,046	$ 336,143

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - shares	Dec. 31, 2022	Jun. 30, 2022
Statement of Financial Position [Abstract]
Series A voting preferred stock, shares issued	0	0
Series A voting preferred stock, shares outstanding	0	0
Redeemable, convertible preferred stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	21,090,218,148	21,090,218,148
Common stock, shares outstanding	21,090,218,148	21,090,218,148

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Sales	$ 38,230	$ 155,680	$ 90,168	$ 155,680
Cost of goods sold	7,998	1,551,007	35,498	1,551,007
Gross profit	30,232	(1,395,327)	54,670	(1,395,327)
Selling, general and administrative expenses
Selling expense	670	0	5,406	0
General and administrative expense	124,669	358,113	272,592	656,179
	125,339	358,113	277,998	656,179
Loss from operations	(95,107)	(1,753,440)	(223,328)	(2,051,506)
Other income (expenses)
Interest expense	(68,001)	(47,618)	(132,540)	(80,859)
Other income	34,987	0	34,993	35
	(33,014)	(47,618)	(97,547)	(80,824)
Loss before income taxes	(128,121)	(1,801,058)	(320,875)	(2,132,330)
Income tax provision	0	0	0	0
NET LOSS	(128,121)	(1,801,058)	(320,875)	(2,132,330)
Less: net loss attributable to non-controlling interest	(3,552)	0	(13,970)	0
NET LOSS ATTRIBUTABLE TO AMERICA GREAT HEALTH	(124,569)	(1,801,058)	(306,905)	(2,132,330)
Foreign currency transaction	330	0	406	0
COMPREHENSIVE LOSS ATTRIBUTABLE TO AMERICA GREAT HEALTH	$ (124,239)	$ (1,801,058)	$ (306,499)	$ (2,132,330)
BASIC AND DILUTED LOSS PER SHARE (in Dollars per share)	$ 0	$ 0	$ 0	$ 0
BASIC AND DILUTED (in Shares)	21,090,218,148	21,073,788,938	21,090,218,148	21,072,327,669

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Jun. 30, 2021		$ 3,087,869	$ (3,555,696)			$ (467,827)
Balance (in Shares) at Jun. 30, 2021	21,070,866,399
Imputed Interest		2,814				2,814
Net loss			(331,272)			(331,272)
Balance at Sep. 30, 2021		3,090,683	(3,886,968)			(796,285)
Balance (in Shares) at Sep. 30, 2021	21,070,866,399
Balance at Jun. 30, 2021		3,087,869	(3,555,696)			(467,827)
Balance (in Shares) at Jun. 30, 2021	21,070,866,399
Imputed Interest						5,537
Net loss						(2,132,330)
Balance at Dec. 31, 2021		3,093,406	(5,688,026)			(2,594,620)
Balance (in Shares) at Dec. 31, 2021	21,075,888,239
Balance at Sep. 30, 2021		3,090,683	(3,886,968)			(796,285)
Balance (in Shares) at Sep. 30, 2021	21,070,866,399
Issuance of common stock for debt (in Shares)	5,021,840
Imputed Interest		2,723				2,723
Net loss			(1,801,058)			(1,801,058)
Balance at Dec. 31, 2021		3,093,406	(5,688,026)			(2,594,620)
Balance (in Shares) at Dec. 31, 2021	21,075,888,239
Balance at Jun. 30, 2022		4,619,991	(8,421,849)	$ (58,783)	$ 160	$ (3,860,481)
Balance (in Shares) at Jun. 30, 2022	21,090,218,148					21,090,218,148
Imputed Interest		5,206				$ 5,206
Original issue discount on debt		15,200				15,200
Gain/loss on exchange rate					76	76
Net loss			(182,336)	(10,418)		(192,754)
Balance at Sep. 30, 2022		4,640,397	(8,604,185)	(69,201)	236	(4,032,753)
Balance (in Shares) at Sep. 30, 2022	21,090,218,148
Balance at Jun. 30, 2022		4,619,991	(8,421,849)	(58,783)	160	$ (3,860,481)
Balance (in Shares) at Jun. 30, 2022	21,090,218,148					21,090,218,148
Imputed Interest						$ 5,206
Net loss						(320,875)
Balance at Dec. 31, 2022		4,640,397	(8,728,754)	(72,753)	566	$ (4,160,544)
Balance (in Shares) at Dec. 31, 2022	21,090,218,148					21,090,218,148
Balance at Sep. 30, 2022		4,640,397	(8,604,185)	(69,201)	236	$ (4,032,753)
Balance (in Shares) at Sep. 30, 2022	21,090,218,148
Gain/loss on exchange rate					330	330
Net loss			(124,569)	(3,552)		(128,121)
Balance at Dec. 31, 2022		$ 4,640,397	$ (8,728,754)	$ (72,753)	$ 566	$ (4,160,544)
Balance (in Shares) at Dec. 31, 2022	21,090,218,148					21,090,218,148

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash Flows from Operating Activities
Net loss	$ (320,875)	$ (2,132,330)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	2,952	0
Original issue discount on debt	15,200	0
Imputed interest	5,206	5,537
Changes in operating Assets and Liabilities:
Accounts receivable	192	0
Prepaid investment	0	(100,000)
Other receivable	0	(14,487)
Other long term asset	2,000	0
Inventory	2,110	(64,439)
Accounts payable	5,376	1,694,709
Customer advances	41,699	0
Other liabilities	16,137	0
Other payable	13,460	0
Tax payable	905	(800)
Net cash used in operating activities	(215,638)	(611,810)
Cash Flows from Investing Activities
Purchase of property and equipment	(44,420)	(16,852)
Net cash provided by investing activities	(44,420)	(16,852)
Cash Flows from Financing Activities
Short term loan	(4,182)	0
Long term loan	230,897	537,368
Advances from related party	128,519	134,122
Repayment to related party	(107,028)	(232,700)
Net cash provided by financing activities	248,206	438,790
Effect of exchange rate changes on cash	406	0
Net increase in cash	(11,446)	(189,872)
Cash beginning of period	62,643	396,136
Cash end of period	51,197	206,264
Interest paid	0	0
Taxes paid	800	800
Non-cash transactions
Shares issued for equity investment	$ 0	$ 0

NATURE OF BUSINESS

NATURE OF BUSINESS	6 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 NATURE OF BUSINESS History and Organization America Great Health, formerly Crown Marketing, is a Wyoming corporation (the "Company"). A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang. In connection with the change of control, the Company sold to its former majority shareholder a subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations. On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health. On March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California. On June 24, 2019, the Company registered a wholly owned subsidiary in China, US-China Mega Beauty Health Industry Development Co., LTD. The subsidiary is mainly engaged in merger and acquisition, investment and financing, and marketing of medical equipment and health products in China. On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day-to-day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. This transaction was completed in May 2021 On December 7, 2020, the Company’s wholly-owned Californian subsidiary, America Great Health, entered into a Cooperation Agreement with Brilliant Healthcare Limited (“Brilliant”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purpose of promoting and developing stem cell related product’s R&D, production, sales, raw material procurement, mergers and acquisitions, and consulting services. After the formation of the JV company is completed, the Company shall invest US$4.2 million in the JV Company within the next 24 months for a 60% equity ownership in the JV Company. Brilliant shall transfer its patented technology to the JV Company as its capital contribution, to account for a 40% equity interest in the JV Company. As a condition for AAGH to obtain 60% equity in the JV company and a as the founder of Brilliant, Dr. Aihua Guo agrees to transfer its patent to the JV company as its share of contribution, and AAGH also agrees to pay Dr. Aihua Guo additional compensation, which includes: (i) AAGH transfers 300 million original shares of AAGH to Dr. Aihua Guo at no cost, valuing at $15 million; (ii) AAGH pays Dr. Aihua Guo a one-time cash compensation of $3 million with the following payment schedule: AAGH agrees to pay $500,000 to Dr. Aihua Guo six months from the date of signing of this Agreement, $1.5 million to Dr. Aihua Guo 12 months from the date of signing of this Agreement, and $1 million to Dr. Aihua Guo 24 months from the date of signing of this Agreement. In June 2021, the JV Company was established in Hainan, China as “Sijinsai (Hainan) Biological Tech Ltd.” On July 9, 2021, the Company paid its first investment of $50,000. On May 18, 2021, the Company and David Tsai (“Dr. Tsai”), a pioneer in anti-cancer peptide research and invention in the United States, entered into a Cooperation Agreement, in which Dr. Tsai shall provide to the Company theories, technologies, methods, sources of raw materials, processing and production techniques, quality standards, quality control methods and other information and details related to his anti-cancer protein peptides, oral insulin and activation technology. Dr. Tsai shall also be responsible for the whole process of technology and product production, application and implementation, as well as professional technical support, consultation and cooperation in the process of product verification, publicity, promotion and sales. Currently, several patents are in the application process, and several products are in the process of getting ready for production. On September 3, 2021, the Company entered into an Assets Acquisition Agreement with Wang’s Property Investment & Management LLC to purchase 53 units in 19 real estate properties appraised at $7,626,286.37 for a purchase price of $7,000,000. The purchase price shall be paid as follows: (i) $1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence. On September 9, 2021, the Company entered into a Supplemental Assets Acquisition Agreement with Wang’s Property Investment & Management LLC to amend and clarify that (i) it was purchasing 19 real estate properties which includes 53 units appraised at $7,626,286.37 for a purchase price of $7,000,000 and (ii) that it will waive and not conduct due diligence in order for the transaction to proceed. The acquisition has not been consummated. On November 4, 2021, the Company set up a 100% owned subsidiary Nutrature Health LLC. On November 11, 2021, America Great Health (the “Company”) entered into an Advisory Committee Member Consulting Agreement with Dr. Kevin Buckman MD (“Consultant”). Pursuant to the Agreement, Consultant is to provide advisory services, as a member to the Advisory Committee to the Board of Directors of the Company, including without limitation, assisting GOF Biotechnologies Inc. in its new drug approval process for oral insulin and Amylase X. Consultant shall be compensated with a warrant to purchase 500,000 shares of the Company at $0.01 per share within 24 months and a warrant at each of the following stages: IND application, Phase I clinical trials, Phase II clinical trials, Phase III clinical trials and the sale of GOF Biotechnologies Inc. the license of oral insulin and Amylase X at Phase I or Phase II clinical trials stages. This Agreement shall be for an initial one-year term and shall renew automatically for successive one-year terms up to a maximum of three (3) years unless terminated by either party pursuant to the Agreement. The 500,000 shares were issued free in April 20, 2022. On November 15, 2021, the Company set up a 100% owned subsidiary GOF Biotechnologies Inc. GOF is 75% majority owned (60,000,000 shares of common stock) by the Company and the remaining 25% of its issued and outstanding shares (20,000,000 shares of common stock) are held by Men Hwei, Tsai. On December 31, 2021, the Company entered into a Supplementary Agreement with Zhigong Lin to amend his prior employment agreement with the Company dated August 31, 2021. The Supplement Agreements provides, inter alia, that Zhigong Lin will be appointed Chief Executive Officer of GOF. The employment agreement and supplement agreement were both terminated by the end of July without the issuance of any GOF shares. On February 4, 2021, the Company set up a 100% owned subsidiary, International Institute of Great Healthcare, Inc. (“IIGH”) under the laws of the State of California. IIGH will bring together doctors and professional-level experts from different countries and regions in the world to the research fields involving bio medicine, clinic medicine, health management, information technology, data analysis, software development, artificial intelligence, industrial planning, financial investment, etc. On November 25,2022, the Company signed a supplementary agreement with Men Hwei, Tsai who is an unrelated party. The Company A agrees that if the patent is sold or transferred, Men Hwei, Tsai or Men Hwei, Tsai's successor may receive a 25% gain on the transfer or sale of the interest. The Company agrees to give Men Hwei, Tsai an additional 20 million AAGH shares. The Company allows Men Hwei, Tsai to use three years (from November 26, 2022 to November 25, 2025) find investors each with more than US$10 million investment. In case that no investor is found within three years, Men Hwei, Tsai agrees to return the patent to the Company, and both parties will continue to cooperate in accordance with the original contract on May 18, 2021. If Men Hwei, Tsai finds an investor with an investment of at least US$10 million within three years, and the process for Men Hwei, Tsai and its investors to apply for a new drug may last for several years, then Men Hwei, Tsai agrees that the Company will use the patented technology to develop dietary supplement that are helpful to Alzheimer’s disease. The Company will be responsible for marketing the dietary supplement. Men Hwei, Tsai is entitled to commission equaling to 8% of sales price. On November 26, 2022, the Company signed a supplementary agreement with Men Hwei, Tsai who is an unrelated party and transferred pending anti-dementia patent to Men Hwei, Tsai for $34,978.48. Going Concern The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying condensed consolidated financial statements, the Company has incurred recurring net losses. For the six months ended December 31, 2022, the Company recorded a net loss of $320,875, used cash to fund operating activities of $215,638, and at December 31, 2022, had a shareholders’ deficit of $4,160,544. These factors create substantial doubt about the Company’s ability to continue as a going concern within the next twelve months from the date these financial statements are available to be issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. During the year ended June 30, 2017, the Company’s former majority shareholder sold his shares to an investor group. The new owners’ plans to continue as a going concern revolve around its ability to achieve profitable operations, as well as raise necessary capital to pay ongoing general and administrative expenses of the Company. The ability of the Company to continue as a going concern is dependent on securing additional sources of capital and the success of the Company’s plan. There is no assurance that the Company will be successful in raising the additional capital or in achieving profitable operations. Our cash needs for the six months ended December 31, 2022 were primarily met by loans and advances from current majority shareholder. As of December 31, 2022, we had a cash balance of $51,197. We intend to finance operating costs over the next twelve months with existing cash on hand and advance from current majority shareholder.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). The accompanying unaudited condensed consolidated financial statements of America Great Health, formerly Crown Marketing and Subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the six months ended December 31, 2022 are not necessarily indicative of the results that may be expected for the year ending June 30, 2023. Basis of Consolidation The Condensed Consolidated Financial Statements includes the accounts of the Company and its current wholly owned subsidiaries, America Great Health in California (100%), GOF Biotechnologies in California (75%), International Institute of Great Health in California (100%), Nutrature Health LLC in California (100%), Sijinsai in China (60%), and US-China Mega Beauty Health Industry Development Co., LTD, (100%). Intercompany transactions and accounts were eliminated in consolidation. The following table depicts the identity of the Company’s subsidiaries: Name of Subsidiary Place of Attributable America Great Health in California USA 100 GOF Biotechnologies in California USA 75 International Institute of Great Health in California USA 100 Nutrature Health LLC in California USA 100 Sijinsai in China CHINA 60 US-China Mega Beauty Health Industry Development Co., LTD CHINA 100 Estimates The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services, debt and equity investment. Actual results could differ from those estimates. Foreign Currency Translation Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations. In accordance with ASC 830, “Translation of Financial Statements” the subsidiary’s assets and liabilities booked and recorded at the non-US local functional currency are generally translated into USD for consolidation purposes, using the exchange rate on the balance sheet date, and revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of foreign subsidiary’s financial statements are recorded as a separate component of accumulated other comprehensive income within the statement of stockholders’ equity. The Company’s reporting currency is the United States Dollar (“USD”). The Company’s wholly owned subsidiary of US-China Mega Beauty Health Industry Development Co., LTD. maintains its books and records in its local currency. The Chinese Yuan (“RMB”), which is the functional currency as being the primary currency of the economic environment in which the subsidiary operates. Below is a table with foreign exchange rates used for translation: December 31, Average Quarterly (average rate) Chinese Renminbi (RMB) RMB 6.8973 United States dollar ($) $ 1.00 December 31, Quarter Ended (Closing rate) Chinese Renminbi (RMB) RMB 6.9764 United States dollar ($) $ 1.00 Cash The Company considers all highly liquid debt instruments purchased with maturity periods of three months or less to be cash equivalents. The carrying amounts reported in the accompanying balance sheet for cash and cash equivalents approximate their fair value. The Company’s bank account in the United States is protected by FDIC insurance. The Company’s bank account in the United States is protected by FDIC insurance. As of December 31, 2022 and June 30, 2022, the Company’s bank account in the United States had $57 and $3,194, respectively, within FDIC insurance of $250,000. Revenues Revenue from sale of goods under Topic 606, Revenue from Contracts with Customers, ● executed contract(s) with customers that the Company believes is legally enforceable; ● identification of performance obligation in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation of the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. The Company sells health related products through wholesale and retailers. Substantially all of the Company’s revenue is derived from product sales. The Company considers purchase orders to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year, and virtually all of the Company’s contracts are short-term. The Company recognizes revenue for the transfer of promised goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. The Company typically satisfies its performance obligations in contracts with customers upon shipment of the goods. The Company does not have any contract assets since the Company has an unconditional right to consideration when the Company has satisfied its performance obligation and payment from customers is not contingent on a future event. Generally, payment is due from customers within 40 to 60 days of the invoice date, and the contracts do not have significant financing components nor variable consideration. Returns and allowances are not a significant aspect of the revenue recognition process as historically they have been immaterial. All of the Company’s contracts have a single performance obligation satisfied at a point in time and the transaction price is stated in the contract, usually as a price per unit. All estimates are based on the Company’s historical experience; complete satisfaction of the performance obligation, and the Company’s best judgment at the time the estimate is made. Historically, sales returns have not significantly impacted the Company’s revenue. Product Revenue A majority of the Company’s sales are for products sold at a point in time and shipped to customers, for which control is transferred to the customer as goods are delivered to the third-party carrier for shipment. The Company receives payment for the sale of products at the time customers place orders and payment is required prior to shipment. The Company does not recognize assets associated with costs to obtain or fulfill a contract with a customer. Shipping and handling activities are performed upon delivery to the third-party carrier for shipment. The Company accounts for these activities as fulfillment costs. Therefore, the Company recognizes the costs of these activities when revenue for the goods is recognized. Shipping and handling costs are included in cost of sales for all periods presented. Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, for estimated excess, obsolescence, or impaired balances. For the six months ended December 31, 2022 and 2021, the Company has not made provision for inventory in regards to slow moving or obsolete items. As of December 31, 2022 and June 30, 2022, inventories amounted to $113,949 and $116,060, respectively. Equity Method Investments We apply the equity method of accounting to investments when we have significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. The Company’s proportionate share of the net income (loss) resulting from these investments is reported under the line item captioned “equity investment” in our Consolidated Statements of Operations. The carrying value of our equity method investments is reported in equity investment in the Consolidated Balance Sheets. The Company’s equity method investments are reported at cost and adjusted each period for the Company’s share of the investee’s income or loss and dividend paid, if any. The Company’s share of the investee’s income or loss is recorded on a one quarter lag for all equity method investments. The Company classifies distributions received from equity method investments using the cumulative earnings approach on the Consolidated Statements of Cash Flows. The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable. The Company recorded no other-than-temporary impairment charges related to its equity method investments during the six months ended December 31, 2022 and 2021. Fair Value Measurements Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if available without undue cost and effort. The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature. Loss per Share Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the six months ended December 31, 2022 and 2021, as there are no potential shares outstanding that would have a dilutive effect. Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company did not recorded a valuation allowance against its deferred tax assets as of December 31, 2022, and June 30, 2022. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes. Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (FASB) issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which requires an entity to utilize a new impairment model known as the current expected credit loss (CECL) model to estimate its lifetime “expected credit loss” and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. In November 2019, the FASB issued ASU 2019-10, Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which defers the effective date of ASU 2016-13 to fiscal years beginning after December 15, 2022 for all entities except SEC reporting companies that are not smaller reporting companies. ASU 2016-13 will be effective for the Company beginning January 1, 2023. The Company believes that the adoption of ASU 2016-13 will impact account receivable, inventory, due from the related parties and property and equipment on its financial statements. In July 2017, the FASB issued Accounting Standards Update 2017-11, “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II)”, which is the replacement of the Indefinite Deferral for Mandatory Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatory Redeemable Non-controlling Interests with a Scope Exception. The amendments in Part I of this Update that relate to the recognition, measurement, and earnings per share of certain freestanding equity-classified financial instruments that include down round features affect entities that present earnings per share in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in Part II of this Update do not have an accounting effect. The amendments in Part I of the update are effective for fiscal year, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is assessing the impact to its accounting practices and financial reporting procedures as a result of the issuance of this standard. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or is not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

DEPOSITS

DEPOSITS	6 Months Ended
	Dec. 31, 2022
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	NOTE 3 DEPOSITS As of December 31, 2022 and June 30, 2022, deposits amounted to $11,836 and $13,836, respectively. Deposits are rent deposits.

INVENTORY

INVENTORY	6 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	NOTE 4 INVENTORY As of December 31, 2022 and June 30, 2022, inventory consisted of the following: December 31, June 30, Raw materials $ 65,900 $ 62,348 Finished goods 48,049 53,712 Total Inventory $ 113,949 $ 116,060

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 5 RELATED PARTY TRANSACTIONS During the six months ended December 31, 2022, the Company's current majority shareholder advanced $128,519 to the Company as working capital and the Company repaid $107,028 to the shareholder. As of December 31, 2022 and June 30, 2022, the Company owed its current majority shareholder of $595,350 and $573,859, respectively. The advances are non-interest bearing and are due on demand. Imputed interest amounted $0 and $2,723 for the three months ended December 31, 2022 and 2021 and was recorded as paid in capital, respectively. Imputed interest amounted $5,206 and $5,537 for the six months ended December 31, 2022 and 2021 and was recorded as paid in capital, respectively.

SHORT TERM LOAN

SHORT TERM LOAN	6 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Short-Term Debt [Text Block]	NOTE 6 SHORT TERM LOAN As of December 31, 2022 and June 30, 2022, short term loan amounted to $179,750 and $183,932 from unrelated third parties, respectively. On September 15, 2022, the Company paid interest of $3,178 on two short term loans of $50,000 due on July 10, 2022 and $10,000 due on August 1, 2022. The Company then re-entered an agreement of a new short-term loan of $60,000. The loan has an annual interest rate of 18% and the principal and interest are due on February 28, 2023. On September 15, 2022, the Company paid interest of $3,616 on two short term loans, each with $50,000 due on July 26, 2022, and August 1, 2022, and paid $20,000 of principal in January 2023. The Company then re-entered an agreement of a new short-term, interest free loan of $80,000. The principal is due on February 28, 2023. The Company will issue 1,600,000 shares of the Company stocks to the party as a reward. These shares has not been issued as of the date of this 10Q released. The third loan amount is $2,871 which has 8-month short term. The latest loan occurred on November 2, 2022, the Company entered an agreement of short-term loan of $25,000. The Company will repay $37,475, with a fixed repayment of $329 every business day from November 10, 2022.

LONG TERM LOAN

LONG TERM LOAN	6 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Long-Term Debt [Text Block]	NOTE 7 LONG TERM LOAN As of December 31, 2022 and June 30, 2022, long term loan amounted to $1,452,790 and $1,221,892, respectively. The loan has an annual interest rate of 20%, except that the received long term loan on September 9, 2022 has an annual interest rate of 16%. The principal and interest are due in five years. Interest expense incurred for the three months ended December 31, 2022 and 2021 amounted to $56,973 and $44,803, respectively. Interest expense incurred for the six months ended December 31, 2022 and 2021 amounted to $109,897 and $75,230, respectively. As of December 31, 2022, long term loan consisted of the following: Principal Interest Balance Received long term loan on April 27, 2021 $ 200,000 $ 67,178 $ 267,178 Received long term loan on June 3, 2021 290,000 91,529 381,529 Received long term loan on June 4, 2021 50,000 15,753 65,753 Received long term loan on June 23, 2021 30,000 9,140 39,140 Received long term loan on July 12, 2021 10,000 2,942 12,942 Received long term loan on September 1, 2021 60,000 15,978 75,978 Received long term loan on September 22, 2021 50,000 12,740 62,740 Received long term loan on September 27, 2021 50,000 12,603 62,603 Received long term loan on September 30, 2021 10,000 2,504 12,504 Received long term loan on October 29, 2021 12,138 2,847 14,985 Received long term loan on November 9, 2021 50,000 11,425 61,425 Received long term loan on November 16, 2021 140,000 31,452 171,452 Received long term loan on November 18, 2021 50,000 11,178 61,178 Received long term loan on November 29, 2021 20,000 4,351 24,351 Received long term loan on November 30, 2021 10,000 2,170 12,170 Received long term loan on September 9, 2022 100,000 4,953 104,953 Received long term loan on October 13, 2022 21,000 909 21,909 Total $ 1,153,138 $ 299,652 $ 1,452,790 On May 5, 2021, the Company issued 10,000,000 shares to an unrelated party as collateral for a loan of $200,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on April 27, 2021. On May 31, 2021, the Company agreed 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed $20,000 on June 3, 2021 and $30,000 on June 23, 2021 and issued 200,000 shares on June 18, 2021 and 240,000 shares on October 28, 2021 with 60,000 shares unissued. On June 18, 2021, the Company issued an aggregate of 2,850,000 shares to 5 unrelated parties as collateral for loans of $270,000. One party with a loan of $100,000 was also awarded 100,000 bonus shares beside the 1,000,000 shares. The loans have an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 3, 2021. On June 18, 2021, the Company issued 500,000 shares to an unrelated party as collateral for a loan of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 4, 2021. On October 28, 2021, the Company issued 80,000 shares to an unrelated party as collateral for loans of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on July 12, 2021. On October 28, 2021, the Company issued 1,540,000 shares to an unrelated party as collateral for loans of $60,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 1, 2021. On October 28, 2021, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 22, 2021. On November 22, 2021, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed in September 27, 2021. On November 22, 2021, the Company issued 100,000 shares to an unrelated party as collateral for loans of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in one year. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 30, 2021. On November 22, 2021, the Company issued 161,840 shares to an unrelated party as collateral for loans of $12,138. The loan has an annual interest rate of 20%. The principal and interest are due in one year. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on October 29, 2021. On November 22, 2021, the Company issued 400,000 shares to an unrelated party as collateral for loans of $40,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 16, 2021. On November 22, 2021, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 9, 2021. On November 29, 2021, the Company issued 1,000,000 shares to an unrelated party as collateral for a loan of $100,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 16, 2021. On February 2, 2022, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 19, 2021. On February 2, 2022, the Company issued 200,000 shares to an unrelated party as collateral for loan of $20,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 29, 2021. On February 2, 2022, the Company issued 100,000 shares to an unrelated party as collateral for loan of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 30, 2021. On September 9, 2022, the Company signed a loan agreement of $100,000 with a five-year term from an unrelated party for a freeze-dryer. The loan has an annual interest rate of 16% with the payments of $3,000 at the end of every moth starting the fourth month after the Company received the proceed and the final payment of $12,000 on September 9, 2027. The Company received the proceed on September 9, 2022. On October 13, 2022, the Company signed a loan agreement of $21,000 with Lian Chen who is an unrelated party. The loan has an annual interest rate of 20%. Total principal and interest of $42,000 are due in five years. The unrelated party would receive 2,625,000 shares from a shareholder designated by the Company. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received $21,000 loan on October 13, 2022. On October 21, 2022, the Company's current majority shareholder Mike Q. Wang transferred 2,625,000 shares to Lian Chen. If after five years, Lian Chen chooses to use stocks to offset the loan, then the Company will issue 2,625,000 shares of common stock to Mike Wang.

CONVERTIBLE, REDEEMABLE PREFERR

CONVERTIBLE, REDEEMABLE PREFERRED STOCK	6 Months Ended
	Dec. 31, 2022
Disclosure Text Block Supplement [Abstract]
Preferred Stock [Text Block]	NOTE 8 CONVERTIBLE, REDEEMABLE PREFERRED STOCK During the year ended June 30, 2016, the Company’s Board of Directors authorized the creation of a series of preferred stock consisting of 1,000,000 shares designated as Series A Preferred Stock (the “Series A”). The Series A is entitled to a dividend of 4%, when and as declared, and is entitled to a liquidation preference of $1 per share plus unpaid dividends. The Series A is redeemable at the option of the Company at any time, in whole or in part, at a price of $1.00 per share, plus 4% per annum thereupon from the date of issuance (the “Stated Value”). In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the Series A shall be entitled to a preferential amount equal to the Stated Value, prior to the holders of common stock receiving any distribution. Each share of Series A is automatically converted on the Conversion Date into a number of shares of common stock of the Company at the initial conversion rate (the “Conversion Rate”), which shall be the Stated Value as of the date of conversion divided by the Market Price. The Market Price for purposes of this Section 5 shall be equal to the average closing sales price of the Common Stock over the 5 previous trading days. The Series A is also subject to adjustments to the Conversion Rate. If the common stock issuable on conversion of the Series A is changed into the same or a different number of shares of any other class or classes of stock, whether by capital reorganization, reclassification, or otherwise (other than a subdivision or combination of shares provided for above), the holders of the Series A shall, upon its conversion, be entitled to receive, in lieu of the common stock which the holders would have become entitled to receive but for such change, a number of shares of such other class or classes of stock that would have been subject to receipt by the holders if they had exercised their rights of conversion of the Series A immediately before that change. In August 2016, the Company filed an amendment to its Articles of Incorporation to increase the number of authorized shares of Series A Preferred Stock from 1,000,000 to 10,000,000. There were no preferred shares outstanding as of December 31, 2022 and June 30, 2022.

SHAREHOLDERS' DEFICIT

SHAREHOLDERS' DEFICIT	6 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 9 SHAREHOLDERS DEFICIT At December 31, 2022 and June 30, 2022, the Company had 21,090,218,148 and 21,090,218,148 shares issued and outstanding, respectively. 1) Shares issued for equity investment On April 6, 2021, the Company issued 70,000,000 shares to a director of Imediplus as collateral in exchange for getting trust of 2,500,000 shares that is 5% of Imediplus. The transaction has not been completed by the reporting date. Equity Investment in Purecell Group: On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Because the company does not have significant control over Purecell, so this is an equity investment. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell" ) in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at fair market value of $0.00001 per share. On May 11, 2021, Aussie Produce PTY LTD (“AP”) signed agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. In order to complete the change of 35,000,000 shares of the Company held by Purecell to AP within the agreed time limit, and to meet the conditions that AP investment funds are in place, the Company and Purecell agreed through consultation that in order to gain time, the Company will issue an additional 35,000,000 shares for AP. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP, at fair market value of $0.00001 per share. On March 31, 2022, the Company issued 1,300,000 shares of common stock to an US individual at $0.075 per share. 2) Shares issued for stock compensation On January 22, 2021, the Company issued an aggregate of 48,220,124 shares of common stock to 28 unrelated parties as compensation for services. The issuance of these shares was recorded at fair market value of $0.00001 per share.48,220,124 shares were issued at fair market value of $482. On March 10, 2021, the Company issued an aggregate of 79,362,534 shares of common stock to 54 unrelated parties as compensation for services. The issuance of these shares was recorded at fair market value of $0.00001 per share. 79,362,534 shares were issued at fair market value of $794. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at fair market value of $0.00001 per share. 50,000,000 shares were issued at fair market value of $500. On April 7, 2021, the Company issued an aggregate of 6,621,905 shares of common stock to 12 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 6,621,905 shares were issued at fair market value of $66. On May 5, 2021, the Company issued an aggregate of 1,300,000 shares of common stock to 6 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 1,300,000 shares were issued at fair market value of $13. On May 18, 2021, the Company issued an aggregate of 7,140,000 shares of common stock to 5 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 7,140,000 shares were issued at fair market value of $71. On May 18, 2021, the Company and David Tsai (“Dr. Tsai”), a pioneer in anti-cancer peptide research and invention in the United States, entered into a Cooperation Agreement, in which Dr. Tsai shall provide to the Company of relevant theories, technologies, methods, sources of raw materials, processing and production techniques, quality standards, quality control methods and other information and details related to his anti-cancer protein peptides, oral insulin and activation technology; Dr. Tsai shall also be responsible for the whole process of technology and product production, application and implementation, as well as professional technical support, consultation and cooperation in the process of product verification, publicity, promotion and sales. As consideration, the Company agreed to grant 8 million shares of AAGH common stock to Dr. Tsai along with certain monthly compensations and sales bonus. On May 26, 2021, the Company issued 2,000,000 shares of common stock to Dr. Tsai as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 2,000,000 shares were issued at fair market value of $20. On May 26, 2021, the Company issued an aggregate of 450,000 shares of common stock to 3 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 450,000 shares were issued at fair market value of $5. On June 18, 2021, the Company issued an aggregate of 11,300,000 shares of common stock to 22 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 11,300,000 shares were issued at fair market value of $113. On February 2, 2022, the Company issued an aggregate of 10,967,465 shares of common stock to 28 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.1195 per share. 10,967,465 shares were issued at fair market value of $1,310,612. On April 1, 2022, the Company issued an aggregate of 75,523 shares of common stock to 1 unrelated party as compensation for services. The issuance of these shares is recorded at fair market value of $0.0685 per share. 75,523 shares were issued at fair market value of $5,173. On April 12, 2022, the Company issued an aggregate of 240,000 shares of common stock to 2 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.06495 per share. 240,000 shares were issued at fair market value of $15,588. On April 20, 2022, the Company issued an aggregate of 500,000 shares of common stock to 1 unrelated party as compensation for services. The issuance of these shares is recorded at fair market value of $0.0595 per share. 500,000 shares were issued at fair market value of $29,750. On May 25, 2022, the Company issued an aggregate of 46,921 shares of common stock to 1 unrelated party as compensation for services. The issuance of these shares is recorded at fair market value of $0.0002 per share. 46,921 shares were issued at fair market value of $9. 3) Shares issued for short term loan as original issue discount On March 18, 2022, the Company issued 400,000 shares of restricted shares of common stock as bonus shares to the lenders with a short term loan amount $100,000, The issuance of these shares is recorded at fair market value of $0.075 per share. 400,000 shares were issued at fair market value of $30,000. On April 12, 2022, the Company issued 240,000 shares of restricted shares of common stock as bonus shares to the lenders with a short term loan amount $60,000, The issuance of these shares is recorded at fair market value of $0.0629 per share. 240,000 shares were issued at fair market value of $15,096. On September 9, 2022, the Company agreed 1,600,000 shares of the Company stocks to the party as a reward. The agreement of these shares is recorded at fair market value of $0.0095 per share, or $15,200 market value, although these shares has not been issued as of the date of this 10Q released. 4) Shares issued for loan as collateral On May 5, 2021, the Company issued 10,000,000 shares to an unrelated party as collateral for a loan of $200,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on April 27, 2021. On May 31, 2021, the Company agreed 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed $20,000 on June 3, 2021 and $30,000 on June 23, 2021 and issued 200,000 shares on June 28, 2021 and 240,000 shares on October 28, 2021 with 60,000 shares unissued. On June 18, 2021, the Company issued an aggregate of 2,850,000 shares to 5 unrelated parties as collateral for loans of $270,000. One party with a loan of $100,000 was also awarded 100,000 bonus shares beside the 1,000,000 shares. The Company recorded the 100,000 bonus shares as stock compensation which was included in above part 2 shares issued for stock compensation. The loans have an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 3, 2021. On June 18, 2021, the Company issued 500,000 shares to an unrelated party as collateral for a loan of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 4, 2021. On October 28, 2021, the Company issued 80,000 shares to an unrelated party as collateral for loans of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on July 12, 2021. On October 28, 2021, the Company issued 1,540,000 shares to an unrelated party as collateral for loans of $60,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 1, 2021. On October 28, 2021, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 22, 2021. On November 22, 2021, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed in September 27, 2021. On November 22, 2021, the Company issued 100,000 shares to an unrelated party as collateral for loans of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in one year. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 30, 2021. On November 22, 2021, the Company issued 161,840 shares to an unrelated party as collateral for loans of $12,138. The loan has an annual interest rate of 20%. The principal and interest are due in one year. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on October 29, 2021. On November 22, 2021, the Company issued 400,000 shares to an unrelated party as collateral for loans of $40,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 1, 2021. On November 22, 2021, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 9, 2021. On November 29, 2021, the Company issued 1,000,000 shares to an unrelated party as collateral for a loan of $100,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 16, 2021. On February 2, 2022, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 19, 2021. On February 2, 2022, the Company issued 200,000 shares to an unrelated party as collateral for loan of $20,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 29, 2021. On February 2, 2022, the Company issued 100,000 shares to an unrelated party as collateral for loan of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 30, 2021. 5) Shares issued in exchange for payable balance On January 28, 2022, the Company signed a company stock and payment exchange agreement with a supplier. The Company offers to pay the supplier the $295,000 for product with 15,000,000 shares of common stock. The 15,000,000 shares of common stock should be transferred to the supplier, or any third party designated by the supplier within 60 days, and no later than March 30, 2022. However, as of February 21, 2023, the Company hasn’t issued any shares of common stock to the supplier for the purchase of products. On January 28, 2022, the Company signed a company stock and payment exchange agreement with a supplier. The Company offers to pay the supplier the $1,100,000 for product with 35,000,000 shares of common stock. The 35,000,000 shares of common stock should be transferred to the supplier, or any third party designated by the supplier within 60 days, and no later than March 30, 2022. However, as of February 21, 2023, the Company hasn’t issued any shares of common stock to the supplier for the purchase of products.

EQUITY INVESTMENT

EQUITY INVESTMENT	6 Months Ended
	Dec. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 10 EQUITY INVESTMENT On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Becausethe company does not have significant control over Purecell, so this is an equity investment. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell" ) in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at fair market value of $0.00001 per share. On May 11, 2021, Aussie Produce PTY LTD (“AP”) signed agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. In order to complete the change of 35,000,000 shares of the Company held by Purecell to AP within the agreed time limit, and to meet the conditions that AP investment funds are in place, the Company and Purecell agreed through consultation that in order to gain time, the Company will issue an additional 35,000,000 shares for AP. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP, at fair market value of $0.00001 per share. The following table summarizes the income statement of Purecell. From 07/01/2022 to 12/31/2022 (Unaudited) Sales $ 107,942 Gross profit 91,913 Net loss (111,616 ) 51% share (56,924 ) The following table provides the summary of equity investment in Purecell. As of December 31, 2022 (Unaudited) Total assets $ 2,186,646 Net assets 1,504,779 51% ownership 767,437 Beginning balance of investment 5,450 Loss on equity investment (5,450 ) Ending balance of investment -

INCOME TAXES

INCOME TAXES	6 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 11 INCOME TAXES As of December 31, 2022, the Company had federal and California income tax net operating loss carryforwards of approximately $6.2 million. These net operating losses will begin to expire 20 years from the date the tax returns are filed. Uncertain Tax Positions Interest associated with unrecognized tax benefits are classified as income tax, and penalties are classified in selling, general and administrative expenses in the statements of operations. For the six months ended December 31, 2022 and 2021, the Company had no unrecognized tax benefits and related interest and penalties expenses. Currently, the Company is not subject to examination by major tax jurisdictions.

LEASE

LEASE	6 Months Ended
	Dec. 31, 2022
Disclosure Text Block [Abstract]
Lessee, Operating Leases [Text Block]	NOTE 12 LEASE The Company has entered into a operating leases agreement with GKT, Alhambra, LP. The lease term of the office space is from December 1, 2020 to November 30, 2023. The current monthly rent including monthly management fee is $4,655.64. The operating lease is listed as separate line item on the Company’s condensed consolidated financial statements and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make lease payments are also listed as a separate line item on the Company’s condensed consolidated financial statements. The Company has entered an operating lease agreement with SoCal Industrial LLC, Irwindale. The lease term of the office space is from June 15, 2021 to May 31, 2023. The current monthly rent including monthly management fee is $1,643.16. The operating lease is listed as separate line item on the Company’s condensed consolidated financial statements and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make lease payments are also listed as a separate line item on the Company’s condensed consolidated financial statements. Operating lease right-of-use assets and liabilities commencing after December 1, 2020 are recognized at commencement date based on the present value of lease payments over the lease term. For the three months ended December 31, 2022 and 2021, the Company recognized approximately $18,897 and $13,967 in total lease costs, respectively. For the six months ended December 31, 2022 and 2021, the Company recognized approximately $37,793 and $27,934 in total lease costs, respectively. Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. Information related to the Company’s operating ROU assets and related lease liabilities are as follows: Six months ended December 31, 2022 Cash paid for operating lease liabilities $ 37,793 Weighted-average remaining lease term 0.79 Weighted-average discount rate 5 % Minimum future lease payments $ 59,428 The following table presents the amortization of the Company’s lease liabilities under ASC 842 for each of the following years ending December 31: 2023 $ 59,428 2024 - 2025 - 2026 - Total minimum payments 59,428 Less: imputed interest (1,359 ) Total lease liability 58,069 Less: short-term lease liability (58,069 ) Long-term lease liability $ -

CONCENTRATION

CONCENTRATION	6 Months Ended
	Dec. 31, 2022
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	NOTE 13 CONCENTRATION Major vendors For the three months ended December 31, 2022, no vendor accounted for 10% or more of the Company’s purchases. For the six months ended December 31, 2022, three vendors accounted for 10% or more of the Company’s purchases and its outstanding accounts payable balances as at quarter-end dates, are presented as follows: For the Six months Ended As of Supplier Purchases Percentage of Account Supplier A $ 21,290 64 % $ - Supplier B 7,000 21 % $ - Supplier C 5,098 15 % $ -

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 14 SUBSEQUENT EVENTS On January 11, 2023, the Company signed a loan agreement of $150,000 with Yajing Sun who is an unrelated party. The loan has an annual interest rate of 20% and one-year term. The Company received the loan on January 12, 2023. On January 12, 2023, the Company’s wholly-owned subsidiary US-China Mega Beauty Health Industry Development Co., LTD signed a cooperation agreement with unrelated parties. The total investment of the project is $7,032,464(RMB 50 million) which has not been received as of the report date. On January 13, 2023, the Company signed a loan cancellation agreement and canceled the agreement signed on September 9, 2022 with Fan Gu who is an unrelated party. On January 13, 2023, the Company paid Fan Gu total principal and interest of $104,175.34. On January 19, 2023, the Company signed a loan agreement of $300,000 with Yunwen Gao who is an unrelated party. The loan has an annual interest rate of 12% and is due one year. The Company received the loan on January 24, 2023.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). The accompanying unaudited condensed consolidated financial statements of America Great Health, formerly Crown Marketing and Subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the six months ended December 31, 2022 are not necessarily indicative of the results that may be expected for the year ending June 30, 2023.
Consolidation, Policy [Policy Text Block]	Basis of Consolidation The Condensed Consolidated Financial Statements includes the accounts of the Company and its current wholly owned subsidiaries, America Great Health in California (100%), GOF Biotechnologies in California (75%), International Institute of Great Health in California (100%), Nutrature Health LLC in California (100%), Sijinsai in China (60%), and US-China Mega Beauty Health Industry Development Co., LTD, (100%). Intercompany transactions and accounts were eliminated in consolidation. The following table depicts the identity of the Company’s subsidiaries: Name of Subsidiary Place of Attributable America Great Health in California USA 100 GOF Biotechnologies in California USA 75 International Institute of Great Health in California USA 100 Nutrature Health LLC in California USA 100 Sijinsai in China CHINA 60 US-China Mega Beauty Health Industry Development Co., LTD CHINA 100
Use of Estimates, Policy [Policy Text Block]	Estimates The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services, debt and equity investment. Actual results could differ from those estimates.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations. In accordance with ASC 830, “Translation of Financial Statements” the subsidiary’s assets and liabilities booked and recorded at the non-US local functional currency are generally translated into USD for consolidation purposes, using the exchange rate on the balance sheet date, and revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of foreign subsidiary’s financial statements are recorded as a separate component of accumulated other comprehensive income within the statement of stockholders’ equity. The Company’s reporting currency is the United States Dollar (“USD”). The Company’s wholly owned subsidiary of US-China Mega Beauty Health Industry Development Co., LTD. maintains its books and records in its local currency. The Chinese Yuan (“RMB”), which is the functional currency as being the primary currency of the economic environment in which the subsidiary operates. Below is a table with foreign exchange rates used for translation: December 31, Average Quarterly (average rate) Chinese Renminbi (RMB) RMB 6.8973 United States dollar ($) $ 1.00 December 31, Quarter Ended (Closing rate) Chinese Renminbi (RMB) RMB 6.9764 United States dollar ($) $ 1.00
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash The Company considers all highly liquid debt instruments purchased with maturity periods of three months or less to be cash equivalents. The carrying amounts reported in the accompanying balance sheet for cash and cash equivalents approximate their fair value. The Company’s bank account in the United States is protected by FDIC insurance. The Company’s bank account in the United States is protected by FDIC insurance. As of December 31, 2022 and June 30, 2022, the Company’s bank account in the United States had $57 and $3,194, respectively, within FDIC insurance of $250,000.
Revenue [Policy Text Block]	Revenues Revenue from sale of goods under Topic 606, Revenue from Contracts with Customers, ● executed contract(s) with customers that the Company believes is legally enforceable; ● identification of performance obligation in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation of the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. The Company sells health related products through wholesale and retailers. Substantially all of the Company’s revenue is derived from product sales. The Company considers purchase orders to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year, and virtually all of the Company’s contracts are short-term. The Company recognizes revenue for the transfer of promised goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. The Company typically satisfies its performance obligations in contracts with customers upon shipment of the goods. The Company does not have any contract assets since the Company has an unconditional right to consideration when the Company has satisfied its performance obligation and payment from customers is not contingent on a future event. Generally, payment is due from customers within 40 to 60 days of the invoice date, and the contracts do not have significant financing components nor variable consideration. Returns and allowances are not a significant aspect of the revenue recognition process as historically they have been immaterial. All of the Company’s contracts have a single performance obligation satisfied at a point in time and the transaction price is stated in the contract, usually as a price per unit. All estimates are based on the Company’s historical experience; complete satisfaction of the performance obligation, and the Company’s best judgment at the time the estimate is made. Historically, sales returns have not significantly impacted the Company’s revenue. Product Revenue A majority of the Company’s sales are for products sold at a point in time and shipped to customers, for which control is transferred to the customer as goods are delivered to the third-party carrier for shipment. The Company receives payment for the sale of products at the time customers place orders and payment is required prior to shipment. The Company does not recognize assets associated with costs to obtain or fulfill a contract with a customer. Shipping and handling activities are performed upon delivery to the third-party carrier for shipment. The Company accounts for these activities as fulfillment costs. Therefore, the Company recognizes the costs of these activities when revenue for the goods is recognized. Shipping and handling costs are included in cost of sales for all periods presented.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, for estimated excess, obsolescence, or impaired balances. For the six months ended December 31, 2022 and 2021, the Company has not made provision for inventory in regards to slow moving or obsolete items. As of December 31, 2022 and June 30, 2022, inventories amounted to $113,949 and $116,060, respectively.
Equity Method Investments [Policy Text Block]	Equity Method Investments We apply the equity method of accounting to investments when we have significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. The Company’s proportionate share of the net income (loss) resulting from these investments is reported under the line item captioned “equity investment” in our Consolidated Statements of Operations. The carrying value of our equity method investments is reported in equity investment in the Consolidated Balance Sheets. The Company’s equity method investments are reported at cost and adjusted each period for the Company’s share of the investee’s income or loss and dividend paid, if any. The Company’s share of the investee’s income or loss is recorded on a one quarter lag for all equity method investments. The Company classifies distributions received from equity method investments using the cumulative earnings approach on the Consolidated Statements of Cash Flows. The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable. The Company recorded no other-than-temporary impairment charges related to its equity method investments during the six months ended December 31, 2022 and 2021.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if available without undue cost and effort. The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature.
Earnings Per Share, Policy [Policy Text Block]	Loss per Share Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the six months ended December 31, 2022 and 2021, as there are no potential shares outstanding that would have a dilutive effect.
Income Tax, Policy [Policy Text Block]	Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company did not recorded a valuation allowance against its deferred tax assets as of December 31, 2022, and June 30, 2022. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (FASB) issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which requires an entity to utilize a new impairment model known as the current expected credit loss (CECL) model to estimate its lifetime “expected credit loss” and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. In November 2019, the FASB issued ASU 2019-10, Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which defers the effective date of ASU 2016-13 to fiscal years beginning after December 15, 2022 for all entities except SEC reporting companies that are not smaller reporting companies. ASU 2016-13 will be effective for the Company beginning January 1, 2023. The Company believes that the adoption of ASU 2016-13 will impact account receivable, inventory, due from the related parties and property and equipment on its financial statements. In July 2017, the FASB issued Accounting Standards Update 2017-11, “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II)”, which is the replacement of the Indefinite Deferral for Mandatory Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatory Redeemable Non-controlling Interests with a Scope Exception. The amendments in Part I of this Update that relate to the recognition, measurement, and earnings per share of certain freestanding equity-classified financial instruments that include down round features affect entities that present earnings per share in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in Part II of this Update do not have an accounting effect. The amendments in Part I of the update are effective for fiscal year, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is assessing the impact to its accounting practices and financial reporting procedures as a result of the issuance of this standard. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or is not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]	The following table depicts the identity of the Company’s subsidiaries: Name of Subsidiary Place of Attributable America Great Health in California USA 100 GOF Biotechnologies in California USA 75 International Institute of Great Health in California USA 100 Nutrature Health LLC in California USA 100 Sijinsai in China CHINA 60 US-China Mega Beauty Health Industry Development Co., LTD CHINA 100
Schedule of Differences between Reported Amount and Reporting Currency Denominated Amount [Table Text Block]	Below is a table with foreign exchange rates used for translation: December 31, Average Quarterly (average rate) Chinese Renminbi (RMB) RMB 6.8973 United States dollar ($) $ 1.00 December 31, Quarter Ended (Closing rate) Chinese Renminbi (RMB) RMB 6.9764 United States dollar ($) $ 1.00

INVENTORY (Tables)

INVENTORY (Tables)	6 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	As of December 31, 2022 and June 30, 2022, inventory consisted of the following: December 31, June 30, Raw materials $ 65,900 $ 62,348 Finished goods 48,049 53,712 Total Inventory $ 113,949 $ 116,060

LONG TERM LOAN (Tables)

LONG TERM LOAN (Tables)	6 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Long-Term Debt Instruments [Table Text Block]	As of December 31, 2022, long term loan consisted of the following: Principal Interest Balance Received long term loan on April 27, 2021 $ 200,000 $ 67,178 $ 267,178 Received long term loan on June 3, 2021 290,000 91,529 381,529 Received long term loan on June 4, 2021 50,000 15,753 65,753 Received long term loan on June 23, 2021 30,000 9,140 39,140 Received long term loan on July 12, 2021 10,000 2,942 12,942 Received long term loan on September 1, 2021 60,000 15,978 75,978 Received long term loan on September 22, 2021 50,000 12,740 62,740 Received long term loan on September 27, 2021 50,000 12,603 62,603 Received long term loan on September 30, 2021 10,000 2,504 12,504 Received long term loan on October 29, 2021 12,138 2,847 14,985 Received long term loan on November 9, 2021 50,000 11,425 61,425 Received long term loan on November 16, 2021 140,000 31,452 171,452 Received long term loan on November 18, 2021 50,000 11,178 61,178 Received long term loan on November 29, 2021 20,000 4,351 24,351 Received long term loan on November 30, 2021 10,000 2,170 12,170 Received long term loan on September 9, 2022 100,000 4,953 104,953 Received long term loan on October 13, 2022 21,000 909 21,909 Total $ 1,153,138 $ 299,652 $ 1,452,790

EQUITY INVESTMENT (Tables)

EQUITY INVESTMENT (Tables)	6 Months Ended
	Dec. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments [Table Text Block]	The following table summarizes the income statement of Purecell. From 07/01/2022 to 12/31/2022 (Unaudited) Sales $ 107,942 Gross profit 91,913 Net loss (111,616 ) 51% share (56,924 ) As of December 31, 2022 (Unaudited) Total assets $ 2,186,646 Net assets 1,504,779 51% ownership 767,437 Beginning balance of investment 5,450 Loss on equity investment (5,450 ) Ending balance of investment -

LEASE (Tables)

LEASE (Tables)	6 Months Ended
	Dec. 31, 2022
Disclosure Text Block [Abstract]
Lease, Cost [Table Text Block]	Information related to the Company’s operating ROU assets and related lease liabilities are as follows: Six months ended December 31, 2022 Cash paid for operating lease liabilities $ 37,793 Weighted-average remaining lease term 0.79 Weighted-average discount rate 5 % Minimum future lease payments $ 59,428
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	The following table presents the amortization of the Company’s lease liabilities under ASC 842 for each of the following years ending December 31: 2023 $ 59,428 2024 - 2025 - 2026 - Total minimum payments 59,428 Less: imputed interest (1,359 ) Total lease liability 58,069 Less: short-term lease liability (58,069 ) Long-term lease liability $ -

CONCENTRATION (Tables)

CONCENTRATION (Tables)	6 Months Ended
	Dec. 31, 2022
Risks and Uncertainties [Abstract]
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	For the six months ended December 31, 2022, three vendors accounted for 10% or more of the Company’s purchases and its outstanding accounts payable balances as at quarter-end dates, are presented as follows: For the Six months Ended As of Supplier Purchases Percentage of Account Supplier A $ 21,290 64 % $ - Supplier B 7,000 21 % $ - Supplier C 5,098 15 % $ -

NATURE OF BUSINESS (Details)

NATURE OF BUSINESS (Details)

3 Months Ended

6 Months Ended

Nov. 25, 2022

Apr. 20, 2022 shares

Mar. 31, 2022 shares

Nov. 11, 2021 $ / shares shares

Sep. 03, 2021 USD ($)

Jul. 09, 2021 USD ($)

Dec. 07, 2020 USD ($)

Jun. 30, 2020 shares

Jan. 19, 2017 USD ($) shares

Dec. 31, 2022 USD ($)

Sep. 30, 2022 USD ($)

Dec. 31, 2021 USD ($)

Sep. 30, 2021 USD ($)

Dec. 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Nov. 26, 2022 USD ($)

Jun. 30, 2022 USD ($)

Nov. 15, 2021 shares

Nov. 04, 2021

Jun. 30, 2021 USD ($)

Apr. 06, 2021

Feb. 10, 2021

Feb. 04, 2021

NATURE OF BUSINESS (Details) [Line Items]

Stock Issued During Period, Shares, Acquisitions (in Shares) | shares

510,000,000

16,155,746,000

Proceeds from Sales of Business, Affiliate and Productive Assets

$ 100

Payments to Acquire Investments

$ 50,000

Number of Units in Real Estate Property

53

Number of Real Estate Properties

19

SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross

$ 7,626,286.37

Payments to Acquire Real Estate

$ 7,000,000

Real Estate, Description of Terms

The purchase price shall be paid as follows: (i) $1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence.

Class of Warrant or Rights, Granted (in Shares) | shares

500,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 0.01

Stock Issued During Period, Shares, New Issues (in Shares) | shares

500,000

1,300,000

Investment Owned, Balance, Shares (in Shares) | shares

20,000,000

Other Commitment

$ 34,978.48

Net Income (Loss) Attributable to Parent

$ (128,121)

$ (192,754)

$ (1,801,058)

$ (331,272)

$ (320,875)

$ (2,132,330)

Net Cash Provided by (Used in) Operating Activities

(215,638)

(611,810)

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest

(4,160,544)

$ (4,032,753)

$ (2,594,620)

$ (796,285)

(4,160,544)

$ (2,594,620)

$ (3,860,481)

$ (467,827)

Cash

$ 51,197

$ 51,197

$ 62,643

Warrants and Rights Outstanding, Term

24 months

Agreement, Description

The Company A agrees that if the patent is sold or transferred, Men Hwei, Tsai or Men Hwei, Tsai's successor may receive a 25% gain on the transfer or sale of the interest. The Company agrees to give Men Hwei, Tsai an additional 20 million AAGH shares. The Company allows Men Hwei, Tsai to use three years (from November 26, 2022 to November 25, 2025) find investors each with more than US$10 million investment. In case that no investor is found within three years, Men Hwei, Tsai agrees to return the patent to the Company, and both parties will continue to cooperate in accordance with the original contract on May 18, 2021. If Men Hwei, Tsai finds an investor with an investment of at least US$10 million within three years, and the process for Men Hwei, Tsai and its investors to apply for a new drug may last for several years, then Men Hwei, Tsai agrees that the Company will use the patented technology to develop dietary supplement that are helpful to Alzheimer’s disease. The Company will be responsible for marketing the dietary supplement. Men Hwei, Tsai is entitled to commission equaling to 8% of sales price.

Purecell Group [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

51%

51%

51%

51%

51%

JV Company [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

60%

Brilliant Healthcare Limited [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

40%

Nutrature Health LLC [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

100%

100%

100%

Gof Biotechnologies, Inc. [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

100%

International Institute of Great Health, Inc. (IIGH) [Member]

NATURE OF BUSINESS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

100%

Gof Biotechnologies, Inc. [Member]

NATURE OF BUSINESS (Details) [Line Items]

Noncontrolling Interest, Ownership Percentage by Parent

75%

Investment Owned, Balance, Shares (in Shares) | shares

60,000,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

25%

Corporate Joint Venture [Member]

NATURE OF BUSINESS (Details) [Line Items]

Payments to Acquire Interest in Joint Venture

$ 4,200,000

Co-venturer [Member] | Common Stock [Member]

NATURE OF BUSINESS (Details) [Line Items]

Payments to Acquire Interest in Joint Venture

15,000,000

Co-venturer [Member] | Cash Distribution [Member]

NATURE OF BUSINESS (Details) [Line Items]

Payments to Acquire Interest in Joint Venture

$ 3,000,000

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Dec. 31, 2022	Jun. 30, 2022	Nov. 04, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Cash, Uninsured Amount (in Dollars)	$ 57	$ 3,194
Cash, FDIC Insured Amount (in Dollars)	250,000
Inventory, Net (in Dollars)	$ 113,949	$ 116,060
America Great Health California [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	100%
GOF Biotechnologies in California [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	75%
International Institute of Great Health [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	100%
Nutrature Health LLC [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	100%		100%
Sijinsai [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	60%
US-China Mega Beauty Health Industry Development Co., LTD [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	100%

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Subsidiaries	6 Months Ended
	Dec. 31, 2022	Nov. 04, 2021
America Great Health California [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	USA
Attributable Equity Interest %	100%
GOF Biotechnologies in California [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	USA
Attributable Equity Interest %	75%
International Institute of Great Health [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	USA
Attributable Equity Interest %	100%
Nutrature Health LLC [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	USA
Attributable Equity Interest %	100%	100%
Sijinsai [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	CHINA
Attributable Equity Interest %	60%
US-China Mega Beauty Health Industry Development Co., LTD [Member]
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Place of Incorporation	CHINA
Attributable Equity Interest %	100%

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Differences between Reported Amount and Reporting Currency Denominated Amount	Dec. 31, 2022
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Foreign currency exchange rate, translation	0.01
China, Yuan Renminbi | Balance Sheet Items [Member]
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Foreign currency exchange rate, translation	0.069764
China, Yuan Renminbi | Income Statement Items [Member]
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items]
Foreign currency exchange rate, translation	0.068973

DEPOSITS (Details)

DEPOSITS (Details) - USD ($)	Dec. 31, 2022	Jun. 30, 2022
Receivables [Abstract]
Other Receivables	$ 11,836	$ 13,836

INVENTORY (Details) - Schedule

INVENTORY (Details) - Schedule of Inventory, Current - USD ($)	Dec. 31, 2022	Jun. 30, 2022
Schedule Of Inventory Current Abstract
Raw materials	$ 65,900	$ 62,348
Finished goods	48,049	53,712
Total Inventory	$ 113,949	$ 116,060

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - Majority Shareholder [Member] - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2022
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Proceeds from Related Party Debt			$ 128,519
Repayments of Related Party Debt			107,028
Due to Related Parties, Current	$ 595,350		595,350		$ 573,859
Imputed Interest	$ 0	$ 2,723	$ 5,206	$ 5,537

SHORT TERM LOAN (Details)

SHORT TERM LOAN (Details)

1 Months Ended

6 Months Ended

Nov. 10, 2022 USD ($)

Sep. 15, 2022 USD ($)

Sep. 09, 2022 shares

Mar. 18, 2022 USD ($) shares

Jan. 28, 2022 shares

Oct. 28, 2021 shares

Jun. 28, 2021 shares

Jun. 18, 2021 shares

Jan. 31, 2023 USD ($)

Dec. 31, 2022 USD ($)

Nov. 02, 2022 USD ($)

Jun. 30, 2022 USD ($)

SHORT TERM LOAN (Details) [Line Items]

Short-Term Debt

$ 179,750

$ 183,932

Interest Paid, Excluding Capitalized Interest, Operating Activities

$ 3,616

Number of loan agreements

2

Debt Instrument, Face Amount

$ 100,000

Debt Instrument, Interest Rate, Stated Percentage

18%

16%

20%

Repayments of Short-Term Debt

$ 20,000

Stock Issued During Period, Shares, Other (in Shares) | shares

1,600,000

400,000

15,000,000

240,000

200,000

1,000,000

Short-Term Debt [Member]

SHORT TERM LOAN (Details) [Line Items]

Interest Paid, Excluding Capitalized Interest, Operating Activities

$ 3,178

Number of loan agreements

2

Stock Issued During Period, Shares, Other (in Shares) | shares

1,600,000

Short Term Loan #1 [Member]

SHORT TERM LOAN (Details) [Line Items]

Debt Instrument, Face Amount

$ 50,000

Short Term Loan #2 [Member]

SHORT TERM LOAN (Details) [Line Items]

Debt Instrument, Face Amount

10,000

Short Term Loan #3 [Member]

SHORT TERM LOAN (Details) [Line Items]

Short-Term Debt

$ 2,871

Debt Instrument, Face Amount

60,000

Short-Term Debt, Terms

8-month short term

Short Term Loan #4 [Member]

SHORT TERM LOAN (Details) [Line Items]

Debt Instrument, Face Amount

50,000

Short Term Loan #5 [Member]

SHORT TERM LOAN (Details) [Line Items]

Debt Instrument, Face Amount

$ 80,000

Short Term Loan #6 [Member]

SHORT TERM LOAN (Details) [Line Items]

Short-Term Debt

$ 37,475

Debt Instrument, Face Amount

$ 25,000

Debt Instrument, Periodic Payment

$ 329

LONG TERM LOAN (Details)

LONG TERM LOAN (Details)

3 Months Ended

6 Months Ended

12 Months Ended

Oct. 13, 2022 USD ($) shares

Sep. 09, 2022 USD ($) shares

May 25, 2022

Apr. 20, 2022

Apr. 12, 2022

Apr. 01, 2022

Mar. 18, 2022 USD ($) shares

Feb. 02, 2022 USD ($) shares

Jan. 28, 2022 shares

Nov. 29, 2021 USD ($) shares

Nov. 22, 2021 USD ($) shares

Oct. 28, 2021 USD ($) shares

Jun. 28, 2021 shares

Jun. 23, 2021 USD ($)

Jun. 18, 2021 USD ($) shares

Jun. 03, 2021 USD ($)

May 31, 2021 USD ($) shares

May 26, 2021

May 18, 2021

May 05, 2021 USD ($) shares

Apr. 07, 2021

Mar. 10, 2021

Dec. 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Dec. 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Jun. 30, 2022 USD ($) shares

Sep. 15, 2022

LONG TERM LOAN (Details) [Line Items]

Long-Term Debt

$ 1,452,790

$ 1,452,790

$ 1,221,892

Debt Instrument, Interest Rate, Stated Percentage

16%

20%

20%

18%

Long-Term Debt, Term

5 years

Interest Expense, Debt

$ 299,652

Stock Issued During Period, Shares, Other (in Shares) | shares

1,600,000

400,000

15,000,000

240,000

200,000

1,000,000

Debt Instrument, Face Amount

$ 100,000

Proceeds from Issuance of Debt

1,153,138

Stock Shares not yet Issued (in Shares) | shares

60,000

Number of Unrelated Parties

1

1

2

1

28

22

3

5

6

12

54

Loans Payable [Member]

LONG TERM LOAN (Details) [Line Items]

Interest Expense, Debt

$ 56,973

$ 44,803

$ 109,897

$ 75,230

Loan #1 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Long-Term Debt, Term

5 years

Stock Issued During Period, Shares, Other (in Shares) | shares

10,000,000

Debt Instrument, Face Amount

$ 200,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Debt Instrument, Term

5 years

Loan #2 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Long-Term Debt, Term

5 years

Stock Issued During Period, Shares, Other (in Shares) | shares

240,000

200,000

500,000

Debt Instrument, Face Amount

$ 50,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Proceeds from Issuance of Debt

$ 30,000

$ 20,000

Stock Shares not yet Issued (in Shares) | shares

60,000

Number of Unrelated Parties

5

Debt Instrument, Term

5 years

Loan #3 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

20%

Long-Term Debt, Term

5 years

Stock Issued During Period, Shares, Other (in Shares) | shares

2,850,000

Debt Instrument, Face Amount

$ 270,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Number of Unrelated Parties

5

Debt Instrument, Term

5 years

Loan # 4 [Member]

LONG TERM LOAN (Details) [Line Items]

Stock Issued During Period, Shares, Other (in Shares) | shares

1,000,000

Debt Instrument, Face Amount

$ 100,000

Loan # 5 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Long-Term Debt, Term

5 years

Stock Issued During Period, Shares, Other (in Shares) | shares

500,000

Debt Instrument, Face Amount

$ 50,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Debt Instrument, Term

5 years

Loan #6 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

80,000

Debt Instrument, Face Amount

$ 10,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Debt Instrument, Term

5 years

Loan # 8 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

500,000

Debt Instrument, Face Amount

$ 50,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Debt Instrument, Term

5 years

Loan # 7 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

1,540,000

Debt Instrument, Face Amount

$ 60,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Debt Instrument, Term

5 years

Loan # 9 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

500,000

Debt Instrument, Face Amount

$ 50,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Debt Instrument, Term

5 years

Loan # 13 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

500,000

Debt Instrument, Face Amount

$ 50,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Debt Instrument, Term

5 years

Loan #10 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

100,000

Debt Instrument, Face Amount

$ 10,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Debt Instrument, Term

1 year

Loan #12 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

400,000

Debt Instrument, Face Amount

$ 40,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Debt Instrument, Term

5 years

Loan #11 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

161,840

Debt Instrument, Face Amount

$ 12,138

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Debt Instrument, Term

1 year

Loan # 14 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

1,000,000

Debt Instrument, Face Amount

$ 100,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Debt Instrument, Term

5 years

Loan #15 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

500,000

Debt Instrument, Face Amount

$ 50,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Debt Instrument, Term

5 years

Loan #17 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

100,000

Debt Instrument, Face Amount

$ 10,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Debt Instrument, Term

5 years

Loan #16 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

200,000

Debt Instrument, Face Amount

$ 20,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Debt Instrument, Term

5 years

Loan #18 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

16%

Debt Instrument, Face Amount

$ 100,000

Proceeds from Issuance of Debt

12,000

Debt Instrument, Periodic Payment

$ 3,000

Loan # 19 [Member]

LONG TERM LOAN (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

20%

Stock Issued During Period, Shares, Other (in Shares) | shares

2,625,000

Debt Instrument, Face Amount

$ 21,000

Long-Term Debt, Maturities, Repayment Terms

During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.

Proceeds from Issuance of Debt

$ 21,000

Debt Instrument, Term

5 years

Loans Payable

$ 42,000

Debt Instrument, Collateral

If after five years, Lian Chen chooses to use stocks to offset the loan, then the Company will issue 2,625,000 shares of common stock to Mike Wang.

Loan # 19 [Member] | Lian Chen [Member]

LONG TERM LOAN (Details) [Line Items]

Stock Issued During Period, Shares, Other (in Shares) | shares

2,625,000

Common Stock [Member] | Loan # 4 [Member]

LONG TERM LOAN (Details) [Line Items]

Stock Issued During Period, Shares, Other (in Shares) | shares

100,000

LONG TERM LOAN (Details) - Sche

LONG TERM LOAN (Details) - Schedule of Long-term Debt Instruments - USD ($)	6 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
Debt Instrument [Line Items]
Principal	$ 1,153,138
Imputed interest	299,652
Balance	1,452,790	$ 1,221,892
Loan Received on April 27, 2021 [Member]
Debt Instrument [Line Items]
Principal	200,000
Imputed interest	67,178
Balance	267,178
Loan Received on June 3, 2021 [Member]
Debt Instrument [Line Items]
Principal	290,000
Imputed interest	91,529
Balance	381,529
Loan received on June 4, 2021 [Member]
Debt Instrument [Line Items]
Principal	50,000
Imputed interest	15,753
Balance	65,753
Loan Received on June 23, 2021 [Member]
Debt Instrument [Line Items]
Principal	30,000
Imputed interest	9,140
Balance	39,140
Loan Received on July 12, 2021 [Member]
Debt Instrument [Line Items]
Principal	10,000
Imputed interest	2,942
Balance	12,942
Loan Received on September 1, 2021 [Member]
Debt Instrument [Line Items]
Principal	60,000
Imputed interest	15,978
Balance	75,978
Loan Received on September 22, 2021 [Member]
Debt Instrument [Line Items]
Principal	50,000
Imputed interest	12,740
Balance	62,740
Loan Received on September 27, 2021 [Member]
Debt Instrument [Line Items]
Principal	50,000
Imputed interest	12,603
Balance	62,603
Loan Received on September 30, 2021 [Member]
Debt Instrument [Line Items]
Principal	10,000
Imputed interest	2,504
Balance	12,504
Loan Received on October 29, 2021 [Member]
Debt Instrument [Line Items]
Principal	12,138
Imputed interest	2,847
Balance	14,985
Loan Received on November 9, 2021 [Member]
Debt Instrument [Line Items]
Principal	50,000
Imputed interest	11,425
Balance	61,425
Loan Received on November 16, 2021 [Member]
Debt Instrument [Line Items]
Principal	140,000
Imputed interest	31,452
Balance	171,452
Loan Received on November 18, 2021 [Member]
Debt Instrument [Line Items]
Principal	50,000
Imputed interest	11,178
Balance	61,178
Loan Received on November 29, 2021 [Member]
Debt Instrument [Line Items]
Principal	20,000
Imputed interest	4,351
Balance	24,351
Loan Received on November 30, 2021 [Member]
Debt Instrument [Line Items]
Principal	10,000
Imputed interest	2,170
Balance	12,170
Loan Received on September 9, 2022 [Member]
Debt Instrument [Line Items]
Principal	100,000
Imputed interest	4,953
Balance	104,953
Loan Received on October 13, 2022 [Member]
Debt Instrument [Line Items]
Principal	21,000
Imputed interest	909
Balance	$ 21,909

LONG TERM LOAN (Details) - Sc_2

LONG TERM LOAN (Details) - Schedule of Long-term Debt Instruments (Parentheticals)		6 Months Ended
	Oct. 13, 2022	Dec. 31, 2022
Loan Received on April 27, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Apr. 27, 2021
Loan Received on June 3, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Jun. 03, 2021
Loan received on June 4, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Jun. 04, 2021
Loan Received on June 23, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Jun. 23, 2021
Loan Received on July 12, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Jul. 12, 2021
Loan Received on September 1, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Sep. 01, 2021
Loan Received on September 22, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Sep. 22, 2021
Loan Received on September 27, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Sep. 27, 2021
Loan Received on September 30, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Sep. 30, 2021
Loan Received on October 29, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Oct. 29, 2021
Loan Received on November 9, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Nov. 09, 2021
Loan Received on November 16, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Nov. 16, 2021
Loan Received on November 18, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Nov. 18, 2021
Loan Received on November 29, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Nov. 29, 2021
Loan Received on November 30, 2021 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Nov. 30, 2021
Loan Received on September 9, 2022 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Sep. 09, 2022
Loan Received on October 13, 2022 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Oct. 13, 2022

CONVERTIBLE, REDEEMABLE PREFE_2

CONVERTIBLE, REDEEMABLE PREFERRED STOCK (Details) - Series A Preferred Stock [Member] - $ / shares	12 Months Ended
	Jun. 30, 2016	Aug. 31, 2016
CONVERTIBLE, REDEEMABLE PREFERRED STOCK (Details) [Line Items]
Preferred Stock, Shares Authorized	1,000,000	10,000,000
Preferred Stock, Dividend Rate, Percentage	4%
Preferred Stock, Liquidation Preference Per Share	$ 1
Preferred Stock, Redemption Terms	The Series A is redeemable at the option of the Company at any time, in whole or in part, at a price of $1.00 per share, plus 4% per annum thereupon from the date of issuance (the “Stated Value”).
Preferred Units, Description	In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the Series A shall be entitled to a preferential amount equal to the Stated Value, prior to the holders of common stock receiving any distribution. Each share of Series A is automatically converted on the Conversion Date into a number of shares of common stock of the Company at the initial conversion rate (the “Conversion Rate”), which shall be the Stated Value as of the date of conversion divided by the Market Price. The Market Price for purposes of this Section 5 shall be equal to the average closing sales price of the Common Stock over the 5 previous trading days.

SHAREHOLDERS' DEFICIT (Details)

SHAREHOLDERS' DEFICIT (Details)																														12 Months Ended
	Sep. 09, 2022 USD ($) $ / shares shares	May 25, 2022 USD ($) $ / shares shares	Apr. 20, 2022 USD ($) $ / shares shares	Apr. 12, 2022 USD ($) $ / shares shares	Apr. 01, 2022 USD ($) $ / shares shares	Mar. 31, 2022 $ / shares shares	Mar. 18, 2022 USD ($) $ / shares shares	Feb. 02, 2022 USD ($) $ / shares shares	Jan. 28, 2022 USD ($) shares	Nov. 29, 2021 USD ($) shares	Nov. 22, 2021 USD ($) shares	Oct. 28, 2021 USD ($) shares	Jun. 28, 2021 shares	Jun. 23, 2021 USD ($)	Jun. 18, 2021 USD ($) $ / shares shares	Jun. 03, 2021 USD ($)	May 31, 2021 USD ($) shares	May 26, 2021 USD ($) $ / shares shares	May 18, 2021 USD ($) $ / shares shares	May 11, 2021 USD ($) shares	May 05, 2021 USD ($) $ / shares shares	Apr. 07, 2021 USD ($) $ / shares shares	Apr. 06, 2021 USD ($) $ / shares shares	Mar. 10, 2021 USD ($) $ / shares shares	Feb. 10, 2021 shares	Jan. 22, 2021 $ / shares shares	Jan. 21, 2021 USD ($)	Jun. 30, 2020 shares	Jan. 19, 2017 shares	Jun. 30, 2022 shares	Dec. 31, 2022 shares	Sep. 15, 2022
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Common Stock, Shares, Issued																														21,090,218,148	21,090,218,148
Common Stock, Shares, Outstanding																														21,090,218,148	21,090,218,148
Stock Issued During Period, Shares, Acquisitions																												510,000,000	16,155,746,000
Number of shareholders																										28
Shares Issued, Price Per Share (in Dollars per share) | $ / shares	$ 0.0095	$ 0.0002	$ 0.0595	$ 0.06495	$ 0.0685	$ 0.075	$ 0.075	$ 0.1195							$ 0.00001			$ 0.00001	$ 0.00001		$ 0.00001	$ 0.00001	$ 0.00001	$ 0.00001		$ 0.00001
Stock Issued During Period, Shares, New Issues			500,000			1,300,000
Stock Issued During Period, Shares, Issued for Services		46,921	500,000	240,000	75,523			10,967,465							11,300,000			450,000	7,140,000		1,300,000	6,621,905	50,000,000	79,362,534		48,220,124
Stock Issued During Period, Value, Issued for Services (in Dollars) | $		$ 9	$ 29,750	$ 15,588	$ 5,173			$ 1,310,612							$ 113			$ 5	$ 71		$ 13	$ 66	$ 500	$ 794			$ 482
Number of Unrelated Parties		1	1	2	1			28							22			3	5		6	12		54
Stock Issued During Period, Shares, Other	1,600,000						400,000		15,000,000			240,000	200,000		1,000,000
Debt Instrument, Face Amount (in Dollars) | $							$ 100,000
Stock Issued During Period, Value, Other (in Dollars) | $	$ 15,200						$ 30,000		$ 295,000
Debt Instrument, Interest Rate, Stated Percentage	16%																														20%	18%
Proceeds from Convertible Debt (in Dollars) | $														$ 30,000		$ 20,000
Stock Shares not yet Issued												60,000
Loan #1 [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other																					10,000,000
Debt Instrument, Face Amount (in Dollars) | $																					$ 200,000
Debt Instrument, Interest Rate, Stated Percentage																					20%
Debt Instrument, Term																					5 years
Long-Term Debt, Maturities, Repayment Terms																					During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.
Loan #2 [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Number of Unrelated Parties															5
Stock Issued During Period, Shares, Other												240,000			200,000		500,000
Debt Instrument, Face Amount (in Dollars) | $																	$ 50,000
Debt Instrument, Interest Rate, Stated Percentage																	20%
Debt Instrument, Term																	5 years
Long-Term Debt, Maturities, Repayment Terms																	During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.
Stock Shares not yet Issued																														60,000
Loan #3 [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Number of Unrelated Parties															5
Stock Issued During Period, Shares, Other															2,850,000
Debt Instrument, Face Amount (in Dollars) | $															$ 270,000
Debt Instrument, Interest Rate, Stated Percentage															20%		20%
Debt Instrument, Term															5 years
Long-Term Debt, Maturities, Repayment Terms															During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.
One party [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Debt Instrument, Face Amount (in Dollars) | $															$ 100,000
Loan # 5 [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other															500,000
Debt Instrument, Face Amount (in Dollars) | $															$ 50,000
Debt Instrument, Interest Rate, Stated Percentage															20%
Debt Instrument, Term															5 years
Long-Term Debt, Maturities, Repayment Terms															During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.
Loan #6 [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other												80,000
Debt Instrument, Face Amount (in Dollars) | $												$ 10,000
Debt Instrument, Interest Rate, Stated Percentage												20%
Debt Instrument, Term												5 years
Long-Term Debt, Maturities, Repayment Terms												During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.
Loan # 7 [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other												1,540,000
Debt Instrument, Face Amount (in Dollars) | $												$ 60,000
Debt Instrument, Interest Rate, Stated Percentage												20%
Debt Instrument, Term												5 years
Long-Term Debt, Maturities, Repayment Terms												During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.
Loan # 8 [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other												500,000
Debt Instrument, Face Amount (in Dollars) | $												$ 50,000
Debt Instrument, Interest Rate, Stated Percentage												20%
Debt Instrument, Term												5 years
Long-Term Debt, Maturities, Repayment Terms												During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.
Loan # 9 [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other											500,000
Debt Instrument, Face Amount (in Dollars) | $											$ 50,000
Debt Instrument, Interest Rate, Stated Percentage											20%
Debt Instrument, Term											5 years
Long-Term Debt, Maturities, Repayment Terms											During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.
Loan #10 [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other											100,000
Debt Instrument, Face Amount (in Dollars) | $											$ 10,000
Debt Instrument, Interest Rate, Stated Percentage											20%
Debt Instrument, Term											1 year
Long-Term Debt, Maturities, Repayment Terms											During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.
Loan #11 [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other											161,840
Debt Instrument, Face Amount (in Dollars) | $											$ 12,138
Debt Instrument, Interest Rate, Stated Percentage											20%
Debt Instrument, Term											1 year
Long-Term Debt, Maturities, Repayment Terms											During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.
Loan #12 [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other											400,000
Debt Instrument, Face Amount (in Dollars) | $											$ 40,000
Debt Instrument, Interest Rate, Stated Percentage											20%
Debt Instrument, Term											5 years
Long-Term Debt, Maturities, Repayment Terms											During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.
Loan # 13 [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other											500,000
Debt Instrument, Face Amount (in Dollars) | $											$ 50,000
Debt Instrument, Interest Rate, Stated Percentage											20%
Debt Instrument, Term											5 years
Long-Term Debt, Maturities, Repayment Terms											During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.
Loan # 14 [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other										1,000,000
Debt Instrument, Face Amount (in Dollars) | $										$ 100,000
Debt Instrument, Interest Rate, Stated Percentage										20%
Debt Instrument, Term										5 years
Long-Term Debt, Maturities, Repayment Terms										During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.
Loan #15 [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other								500,000
Debt Instrument, Face Amount (in Dollars) | $								$ 50,000
Debt Instrument, Interest Rate, Stated Percentage								20%
Debt Instrument, Term								5 years
Long-Term Debt, Maturities, Repayment Terms								During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.
Loan #16 [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other								200,000
Debt Instrument, Face Amount (in Dollars) | $								$ 20,000
Debt Instrument, Interest Rate, Stated Percentage								20%
Debt Instrument, Term								5 years
Long-Term Debt, Maturities, Repayment Terms								During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.
Loan #17 [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other								100,000
Debt Instrument, Face Amount (in Dollars) | $								$ 10,000
Debt Instrument, Interest Rate, Stated Percentage								20%
Debt Instrument, Term								5 years
Long-Term Debt, Maturities, Repayment Terms								During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven.
Imediplus Inc. [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Equity Method Investment, Ownership Percentage																							5%
Purecell Group [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Equity Method Investment, Ownership Percentage																							51%		51%			51%			51%
Purecell Group [Member] | Aussie Produce PTY LTD [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Equity Method Investment, Ownership Percentage																				6%
Supplier [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other									35,000,000
Stock Issued During Period, Value, Other (in Dollars) | $									$ 1,100,000
Bonus [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other															100,000
Dr. Tsai [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share) | $ / shares																		$ 0.00001
Stock Issued During Period, Shares, Issued for Services																		2,000,000	8,000,000
Stock Issued During Period, Value, Issued for Services (in Dollars) | $																		$ 20
Imediplus Inc. [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Acquisitions																							70,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares																							2,500,000
Purecell Group [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Acquisitions																				31,212,000								510,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares																							510,000,000		510,000,000			510,000,000
Number of shareholders																							2		2
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture																							50,000,000
Shares Issued, Price Per Share (in Dollars per share) | $ / shares																		$ 0.00001					$ 0.00001
Sale of Stock, Number of Shares Issued in Transaction																				71,163
Purecell Group [Member] | Aussie Produce PTY LTD [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share) | $ / shares																		$ 0.00001
Proceeds from Issuance or Sale of Equity (in Dollars) | $																				$ 2,340,000
Stock Issued During Period, Shares, New Issues																		35,000,000		35,000,000
Sale of Stock, Number of Shares Issued in Transaction																				68,372
Loans Payable [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share) | $ / shares				$ 0.0629
Stock Issued During Period, Shares, Other				240,000
Debt Instrument, Face Amount (in Dollars) | $				$ 60,000
Loans Payable [Member] | Bonus [Member]
SHAREHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Value, Other (in Dollars) | $				$ 15,096

EQUITY INVESTMENT (Details)

EQUITY INVESTMENT (Details)	Apr. 20, 2022 $ / shares shares	Mar. 31, 2022 $ / shares shares	May 26, 2021 $ / shares shares	May 11, 2021 USD ($) shares	Apr. 06, 2021 $ / shares shares	Feb. 10, 2021 shares	Jan. 22, 2021 $ / shares	Jun. 30, 2020 shares	Jan. 19, 2017 shares	Dec. 31, 2022	Sep. 09, 2022 $ / shares	May 25, 2022 $ / shares	Apr. 12, 2022 $ / shares	Apr. 01, 2022 $ / shares	Mar. 18, 2022 $ / shares	Feb. 02, 2022 $ / shares	Jun. 18, 2021 $ / shares	May 18, 2021 $ / shares	May 05, 2021 $ / shares	Apr. 07, 2021 $ / shares	Mar. 10, 2021 $ / shares
EQUITY INVESTMENT (Details) [Line Items]
Number of shareholders							28
Shares Issued, Price Per Share (in Dollars per share) | $ / shares	$ 0.0595	$ 0.075	$ 0.00001		$ 0.00001		$ 0.00001				$ 0.0095	$ 0.0002	$ 0.06495	$ 0.0685	$ 0.075	$ 0.1195	$ 0.00001	$ 0.00001	$ 0.00001	$ 0.00001	$ 0.00001
Stock Issued During Period, Shares, New Issues	500,000	1,300,000
Stock Issued During Period, Shares, Acquisitions								510,000,000	16,155,746,000
Purecell Group [Member]
EQUITY INVESTMENT (Details) [Line Items]
Equity Method Investment, Ownership Percentage					51%	51%		51%		51%
Aussie Produce PTY LTD [Member] | Purecell Group [Member]
EQUITY INVESTMENT (Details) [Line Items]
Equity Method Investment, Ownership Percentage				6%
Purecell Group [Member]
EQUITY INVESTMENT (Details) [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares					510,000,000	510,000,000		510,000,000
Number of shareholders					2	2
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture					50,000,000
Shares Issued, Price Per Share (in Dollars per share) | $ / shares			0.00001		$ 0.00001
Sale of Stock, Number of Shares Issued in Transaction				71,163
Stock Issued During Period, Shares, Acquisitions				31,212,000				510,000,000
Purecell Group [Member] | Aussie Produce PTY LTD [Member]
EQUITY INVESTMENT (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share) | $ / shares			$ 0.00001
Proceeds from Issuance or Sale of Equity (in Dollars) | $				$ 2,340,000
Stock Issued During Period, Shares, New Issues			35,000,000	35,000,000
Sale of Stock, Number of Shares Issued in Transaction				68,372

EQUITY INVESTMENT (Details) - E

EQUITY INVESTMENT (Details) - Equity Method Investments - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2022
Schedule of Equity Method Investments [Line Items]
Sales	$ 38,230	$ 155,680	$ 90,168	$ 155,680
Gross profit	30,232	(1,395,327)	54,670	(1,395,327)
51% share	(3,552)	$ 0	(13,970)	0
Net assets	326,046		326,046		$ 336,143
Loss on equity investment			0	$ 100,000
Purecell Group [Member]
Schedule of Equity Method Investments [Line Items]
51% ownership	767,437		767,437
Beginning balance of investment			5,450
Loss on equity investment			(5,450)
Ending balance of investment	0		0
Purecell Group [Member]
Schedule of Equity Method Investments [Line Items]
Sales			107,942
Gross profit			91,913
Net loss			(111,616)
51% share			(56,924)
Total assets	2,186,646		2,186,646
Net assets	$ 1,504,779		$ 1,504,779

EQUITY INVESTMENT (Details) -_2

EQUITY INVESTMENT (Details) - Equity Method Investments (Parentheticals)	Dec. 31, 2022	Apr. 06, 2021	Feb. 10, 2021	Jun. 30, 2020
Purecell Group [Member]
Schedule of Equity Method Investments [Line Items]
Share/Ownership	51%	51%	51%	51%

INCOME TAXES (Details)

INCOME TAXES (Details)	Dec. 31, 2022 USD ($)
Foreign Tax Authority [Member]
INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards	$ 6.2

LEASE (Details)

LEASE (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
LEASE (Details) [Line Items]
Operating Lease, Expense	$ 18,897	$ 13,967	$ 37,793	$ 27,934
GKT, Alhambra, LP [Member] | Minimum [Member]
LEASE (Details) [Line Items]
Operating Lease, Expense			4,655.64
SoCal Industrial LLC [Member] | Minimum [Member]
LEASE (Details) [Line Items]
Operating Lease, Expense			$ 1,643.16

LEASE (Details) - Lease, Cost

LEASE (Details) - Lease, Cost	6 Months Ended
	Dec. 31, 2022 USD ($)
Lease, Cost [Abstract]
Cash paid for operating lease liabilities	$ 37,793
Weighted-average remaining lease term	9 months 14 days
Weighted-average discount rate	5%
Minimum future lease payments	$ 59,428

LEASE (Details) - Lessee, Opera

LEASE (Details) - Lessee, Operating Lease, Liability, Maturity - USD ($)	Dec. 31, 2022	Jun. 30, 2022
Lessee Operating Lease Liability Maturity Abstract
2023	$ 59,428
2024	0
2025	0
2026	0
Total	59,428
Less: imputed interest	(1,359)
Total lease liability	58,069
Less: short-term lease liability	(58,069)	$ (70,895)
Long-term lease liability	$ 0	$ 22,991

CONCENTRATION (Details) - Sched

CONCENTRATION (Details) - Schedules of Concentration of Risk, by Risk Factor - Cost of Goods and Service Benchmark [Member] - Supplier Concentration Risk [Member]	6 Months Ended
	Dec. 31, 2022 USD ($)
Supplier A [Member]
Concentration Risk [Line Items]
Purchases	$ 21,290
Percentage of total Purchases	64%
Account Payable	$ 0
Supplier B [Member]
Concentration Risk [Line Items]
Purchases	$ 7,000
Percentage of total Purchases	21%
Account Payable	$ 0
Supplier C [Member]
Concentration Risk [Line Items]
Purchases	$ 5,098
Percentage of total Purchases	15%
Account Payable	$ 0

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - Subsequent Event [Member] ¥ in Millions	Jan. 19, 2023 USD ($)	Jan. 13, 2023 USD ($)	Jan. 12, 2023 USD ($)	Jan. 12, 2023 CNY (¥)	Jan. 11, 2023 USD ($)
SUBSEQUENT EVENTS (Details) [Line Items]
Debt Instrument, Face Amount	$ 300,000				$ 150,000
Debt Instrument, Interest Rate, Stated Percentage	12%				20%
Payments to Acquire Investments			$ 7,032,464	¥ 50
Repayments of Debt		$ 104,175.34
Debt Instrument, Term	1 year